163 related articles for article (PubMed ID: 27569947)
1. Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin for Kidney Transplant Patients With Locally Advanced Transitional Cell Carcinoma: A Single-center Experience.
Wang ZP; Wang WY; Zhu YC; Xiao J; Lin J; Guo YW; Tian Y
Transplant Proc; 2016; 48(6):2076-9. PubMed ID: 27569947
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.
Lorusso V; Manzione L; De Vita F; Antimi M; Selvaggi FP; De Lena M
J Urol; 2000 Jul; 164(1):53-6. PubMed ID: 10840423
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of pre- and postoperative gemcitabine-plus-cisplatin systemic chemotherapy for the treatment of locally advanced urothelial carcinoma in kidney transplant patients.
Zhang P; Zhang XD; Wang Y; Wang W
Transplant Proc; 2013 Nov; 45(9):3293-7. PubMed ID: 24182803
[TBL] [Abstract][Full Text] [Related]
4. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J
J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
Jin JO; Lehmann J; Taxy J; Huo D; Stöckle M; Vogelzang NJ; Steinberg G; Stadler WM
Clin Genitourin Cancer; 2006 Sep; 5(2):150-4. PubMed ID: 17026804
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Pagliaro LC; Millikan RE; Tu SM; Williams D; Daliani D; Papandreou CN; Logothetis CJ
J Clin Oncol; 2002 Jul; 20(13):2965-70. PubMed ID: 12089226
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Dogliotti L; Cartenì G; Siena S; Bertetto O; Martoni A; Bono A; Amadori D; Onat H; Marini L
Eur Urol; 2007 Jul; 52(1):134-41. PubMed ID: 17207911
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Kaufman D; Raghavan D; Carducci M; Levine EG; Murphy B; Aisner J; Kuzel T; Nicol S; Oh W; Stadler W
J Clin Oncol; 2000 May; 18(9):1921-7. PubMed ID: 10784633
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Birtle A; Johnson M; Chester J; Jones R; Dolling D; Bryan RT; Harris C; Winterbottom A; Blacker A; Catto JWF; Chakraborti P; Donovan JL; Elliott PA; French A; Jagdev S; Jenkins B; Keeley FX; Kockelbergh R; Powles T; Wagstaff J; Wilson C; Todd R; Lewis R; Hall E
Lancet; 2020 Apr; 395(10232):1268-1277. PubMed ID: 32145825
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Nogué-Aliguer M; Carles J; Arrivi A; Juan O; Alonso L; Font A; Mellado B; Garrido P; Sáenz A;
Cancer; 2003 May; 97(9):2180-6. PubMed ID: 12712469
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Song YS; Cho JS; Cho KS; Doo SH; Chung BH; Kim SJ; Yang WJ; Song KH; Kim CI; Hong SJ
Urol Int; 2010; 85(1):47-51. PubMed ID: 20234122
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Neri B; Vannini L; Giordano C; Grifoni R; Pantaleo P; Baldazzi V; Crisci A; Lapini A; Raugei A; Carini M
Anticancer Drugs; 2007 Nov; 18(10):1207-11. PubMed ID: 17893522
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J
Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316
[TBL] [Abstract][Full Text] [Related]
14. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
15. Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Lara PN; Meyers FJ; Law LY; Dawson NA; Houston J; Lauder I; Edelman MJ
Cancer; 2004 Jan; 100(1):82-8. PubMed ID: 14692027
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma.
Tsukamoto T; Yonese J; Ohkubo Y; Fukui I
Cancer; 2006 Jun; 106(11):2363-8. PubMed ID: 16649219
[TBL] [Abstract][Full Text] [Related]
18. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
von der Maase H; Andersen L; Crinò L; Weinknecht S; Dogliotti L
Ann Oncol; 1999 Dec; 10(12):1461-5. PubMed ID: 10643537
[TBL] [Abstract][Full Text] [Related]
19. The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Kondo M; Hotta Y; Ando R; Yasui T; Kimura K
Cancer Chemother Pharmacol; 2017 May; 79(5):995-1001. PubMed ID: 28391352
[TBL] [Abstract][Full Text] [Related]
20. SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Geldart T; Chester J; Casbard A; Crabb S; Elliott T; Protheroe A; Huddart RA; Mead G; Barber J; Jones RJ; Smith J; Cowles R; Evans J; Griffiths G
Eur Urol; 2015 Apr; 67(4):599-602. PubMed ID: 25465968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
